Key Takeaways
Use of prescription weight loss medications in the United States has risen substantially in recent years, particularly after the approval of GLP-1 receptor agonists. This evergreen explainer summarizes the best available estimates of what percentage of Americans are currently using these drugs, how use differs across demographic groups, and how coverage and payer type relate to adoption. Where possible, estimates are presented with source types and date context to support long-term relevance.
How Prevalent Are Prescription Weight Loss Drugs in the U.S. Today
As of the most recent national surveys and peer-reviewed analyses through 2024, approximately 10 to 12 percent of U.S. adults report current use of prescription weight loss medications. This represents a notable increase from earlier in the decade, reflecting expanded eligibility, payer coverage updates, and heightened demand following the FDA approval of GLP-1 receptor agonists for chronic weight management. Prevalence estimates vary by age, with higher use observed among middle-aged adults, by gender, with women reporting higher utilization, and by payer status, with privately insured and Medicare Advantage members showing elevated adoption compared to the uninsured.
Age-Related Patterns in GLP-1 and Other Antiobesity Medication Use
Use of prescription antiobesity medications, including GLP-1 agonists, is uncommon among children and adolescents but increases substantially in young adulthood and peaks in middle age. Data from national health interviews and commercial insurance claims indicate that adults aged 18 to 44 have moderate use, adults aged 45 to 64 show the highest prevalence, and use declines somewhat after age 65, though Medicare coverage expansions are reshaping this pattern. These trends reflect both clinical guidelines that emphasize risk-based treatment and payer policies that influence affordability and access.
Age Band and Typical Prevalence (Indicative Ranges)
| Age Group | Approximate Current Use | Source Type and Period |
|---|---|---|
| 18–44 years | 5–8% | NHANES, 2020–2023; payer claims, 2022–2024 |
| 45–64 years | 12–18% | NHANES, 2021–2023; employer and Medicare data, 2023 |
| 65+ years | 7–12% | Medicare Part D, 2023; commercial Medicare Advantage, 2023–2024 |
Gender Differences in Antiobesity Medication Use
Across most age groups and payer types, women are significantly more likely than men to report using prescription weight loss medications. This difference is consistent with broader patterns in obesity treatment, where women more frequently seek and receive pharmacologic support for weight management. The gap is evident in both general obesity medications and in GLP-1-based therapies, though utilization among men is rising as awareness, clinician recommendations, and media coverage expand.
Insurance and Payer Influences on Adoption
Health coverage status strongly correlates with who accesses weight loss medications. Adults with private insurance, particularly through employer plans, and Medicare Advantage members show the highest current use, while the uninsured report the lowest prevalence. Medicare Part D coverage has expanded access for some medications, but formularies and prior-authorization requirements continue to shape uptake. Out-of-pocket costs, even with coverage, can remain a barrier, particularly for newer agents with higher list prices.
Coverage-Related Adoption Indicators
| Payer Type | Approximate Medication Use | Key Influences |
|---|---|---|
| Private Insurance | 12–18% | Employer plan benefits, medical necessity criteria, step therapy |
| Medicare Advantage | 10–15% | Plan design, pharmacy networks, coverage policies |
| Medicare Part D | 6–10% | Formulary placement, prior authorization, cost-sharing |
| Uninsured | Out-of-pocket affordability, limited clinical support |
Clinical Definitions and Measurement Context
For these estimates, prescription weight loss medications include FDA-approved antiobesity drugs such as GLP-1 receptor agonists, phentermine-topiramate, and naltrexone-bupropion, as well as select older agents when used under medical supervision. Prevalence typically derives from self-reported use in national health interview surveys, pharmacy fill data, and insurance claims, each with inherent limitations such as underreporting or variability in adherence. Definitions of current use vary by study, but most sources consider a 30-day or 90-day window to reflect ongoing, intended use rather than a one-time prescription.
Why Percentages Vary by Data Source
Reported percentages depend on whether data come from patient self-disclosure, pharmacy records, or payer adjudication, as well as the specific eligibility criteria applied. Surveys that include only noninstitutionalized adults may miss certain populations, while claims-based data can overestimate use due to automated dispensing without proof of ingestion. Additionally, timing matters: estimates from 2023 and 2024 capture a surge in GLP-1 use, while earlier years reflect a lower baseline. Understanding the source and period helps users interpret how the observed percentage fits into longer-term trends.
What These Trends Imply for Public Health and Policy
The rising percentage of Americans using prescription weight loss medications signals increased demand for obesity treatment and greater acceptance of pharmacotherapy as part of comprehensive care. For public health and payers, this trend underscores the importance of evidence-based coverage policies, affordable access, and integration with lifestyle and behavioral supports. Monitoring these numbers over time will be essential to assess health equity, clinical outcomes, and the long-term value of antiobesity medications across diverse U.S. populations.
Frequently Asked Questions
- What percentage of U.S. adults currently use prescription weight loss drugs? Approximately 10–12% of U.S. adults report current use as of 2023–2024, with higher rates among women and middle-aged adults.
- Has use changed over the past few years? Yes, adoption has increased notably since 2021, driven largely by expanded use of GLP-1 receptor agonists following regulatory approvals and broader payer coverage.
- Are certain age groups more likely to use these medications? Yes, adults aged 45–64 show the highest prevalence, while use is lower among younger adults and seniors, though Medicare coverage is shifting utilization patterns.
- How does insurance status affect use? Uninsured adults report the lowest use, while those with private insurance or Medicare Advantage show substantially higher rates, reflecting access and affordability differences.
- Do these estimates include over-the-counter supplements? No, these percentages refer specifically to FDA-approved prescription antiobesity medications obtained through a healthcare provider.